Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Drug Review Personnel Costs Dropping, Remain “Completely Normal,” FDA Says

Aug 12 2013

• By Derrick Gingery

Related Content

PDUFA Communications Hurt By Sequestration As Late-Stage Meetings Begin

Apr 08 2013

PDUFA, Biosimilar Application Fees To Rise 10.7%; FDA’s Workload Adjuster Needs Work

Aug 01 2013

FDA Spending Less Time On INDs, More On NDAs and BLAs

Aug 06 2012

FDA Drug Review Costs Rise, But Personnel Spending Flattens

Aug 13 2012

PhRMA, BIO’s PDUFA V Application Tracker Could Inform “Course Corrections”

Jun 26 2013

Should FDA Be Forced To Consider Development Time And Cost?

Nov 12 2012

Encore? FDA Could Come Close To Record 2012 NME Count This Year

Jul 29 2013

First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?

May 06 2013

Additional Topics

United States Regulation BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window